Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timo Vesikari

Showing results (81-90 of 211) with videos related to

Pageof 22
Sort By:
BMC Health Services Research|December 16, 2014
Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®Susanne Hartwig, Matti Uhari, Marjo Renko, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
European Journal of Pediatrics|February 24, 2020
Rotavirus vaccination for all children or subgroups only? Comment of the European Academy of Paediatrics (EAP) and the European Society for Paediatric Infectious Diseases (ESPID) recommendation group for rotavirus vaccinationHans Jürgen Dornbusch, Timo Vesikari, Alfredo Guarino, et al.
Clinical and Vaccine Immunology : CVI|August 23, 2013
Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of ageTimo Vesikari, Sven Arne Silfverdal, Florence Boisnard, et al.
The Journal of Infection|October 4, 2019
Continuing rotavirus circulation in children and adults despite high coverage rotavirus vaccination in FinlandJukka Markkula, Maria Hemming-Harlo, Carita Savolainen-Kopra, et al.
The Journal of Pediatrics|December 6, 2003
Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trialPéter Csonka, Minna Kaila, Pekka Laippala, et al.
Human Vaccines & Immunotherapeutics|April 3, 2020
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized studyTimo Vesikari, Ray Borrow, Aino Forsten, et al.
The Pediatric Infectious Disease Journal|January 19, 2016
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same VaccinesTimo Vesikari, Aino Forsten, Veronique Bianco, et al.
Human Vaccines & Immunotherapeutics|November 18, 2015
Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccineTimo Vesikari, Aino Forsten, Veronique Bianco, et al.
Clinical and Vaccine Immunology : CVI|April 24, 2015
Genotype considerations for virus-like particle-based bivalent norovirus vaccine compositionMaria Malm, Kirsi Tamminen, Suvi Lappalainen, et al.
Pageof 22

Showing results (81-90 of 211) with videos related to

Sort By:
Pageof 22
BMC Health Services Research|December 16, 2014
Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®Susanne Hartwig, Matti Uhari, Marjo Renko, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
European Journal of Pediatrics|February 24, 2020
Rotavirus vaccination for all children or subgroups only? Comment of the European Academy of Paediatrics (EAP) and the European Society for Paediatric Infectious Diseases (ESPID) recommendation group for rotavirus vaccinationHans Jürgen Dornbusch, Timo Vesikari, Alfredo Guarino, et al.
Clinical and Vaccine Immunology : CVI|August 23, 2013
Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of ageTimo Vesikari, Sven Arne Silfverdal, Florence Boisnard, et al.
The Journal of Infection|October 4, 2019
Continuing rotavirus circulation in children and adults despite high coverage rotavirus vaccination in FinlandJukka Markkula, Maria Hemming-Harlo, Carita Savolainen-Kopra, et al.
The Journal of Pediatrics|December 6, 2003
Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trialPéter Csonka, Minna Kaila, Pekka Laippala, et al.
Human Vaccines & Immunotherapeutics|April 3, 2020
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized studyTimo Vesikari, Ray Borrow, Aino Forsten, et al.
The Pediatric Infectious Disease Journal|January 19, 2016
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same VaccinesTimo Vesikari, Aino Forsten, Veronique Bianco, et al.
Human Vaccines & Immunotherapeutics|November 18, 2015
Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccineTimo Vesikari, Aino Forsten, Veronique Bianco, et al.
Clinical and Vaccine Immunology : CVI|April 24, 2015
Genotype considerations for virus-like particle-based bivalent norovirus vaccine compositionMaria Malm, Kirsi Tamminen, Suvi Lappalainen, et al.
Pageof 22